← All trials
NCT07218549
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2026
- Primary completion
- Dec 31, 2028
- Completion date
- May 31, 2029
- First posted
- Oct 20, 2025
- Last posted
- Oct 20, 2025
- Enrollment
- 50
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversitySponsor investigator
- Baylor UniversityOfficial
- Baylor UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.